Global Papillary
Thyroid Cancer
Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Papillary thyroid cancer (PTC) also called papillary carcinoma is one of the most common
type of thyroid cancer and it is most curable among other cancers. Follicular cancer,
medullary cancer, and anaplastic cancer are other types of thyroid cancers. The
prevalence rate of papillary thyroid cancer is 0.5-10 per 100,000 population. Papillary
thyroid carcinoma presents as asymptomatic thyroid nodules, increasing the size of
nodule in patient is the primary symptom for this disease. Cough, dyspnea and dysphagia
are the severe stage symptoms of papillary thyroid cancer and lump or swelling in the
neck parts are the physical symptoms of the papillary thyroid cancer. Age, gender and
exposure to radiation affect the risk of papillary thyroid cancer. Itis more common in
women than in men, and often occurs before age 45. People who have been exposed to
large amounts of radiation, or who have had radiation therapy for medical problems in
the head and neck have a more chance of getting thyroid cancer.
To treat papillary thyroid cancer various methods are available which include surgical
procedure, iodine therapy, thyroxin treatment and external radiotherapy. In surgical
procedure, surgeon removes affected tissue from the neck. Iodine therapy is given to the
patient post operatively to destroy normal thyroid remnants. External radiotherapy is
indicated for the patients with age group 45 years and above.
Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1659
The growth of thyroid tumor cells are controlled by thyrotropin and is inhibited by
thyroxin, inhibition of thyrotropin with thyroxin increase the recurrence of survival rates.
Report
Description
Report Description
The most commonly used drugs in the treatment of papillary thyroid cancer are
levothyroxine and radioiodine and antineoplastic agents such as cisplatin, doxorubicin
and these drugs are used after the surgery and radiation therapy.
Papillary Thyroid Cancer Market has been classified on the basis of treatment and end
user.
Papillary Thyroid Cancer by Treatment
Surgery
Iodine Therapy
Thyroxin Treatment
External Radiotherapy
Chemotherapy
Cisplatin
Doxorubicin
Drugs
Levothyroxine
Radioiodine
Report
Description
Report Description
Papillary Thyroid Cancer by End User
Hospital
Oncology Centres
Hospital Pharmacies
Retail Pharmacies
In 2015, According to American Cancer Society (ACS), thyroid cancer accounts 47,230 in
women and 15,220 in men in the U.S. and the incidence rate and mortality rate of thyroid
cancer is high in women than in men. Thus, the increasing prevalence and incidence rate
of thyroid cancers is expected to drive the overall papillary thyroid cancer. Increasing
awareness about the cancer disease, raising government funds and reimbursement
policies from Medicare and Medicaid are the key factors which are expected to propel
the overall papillary thyroid cancer treatment market. The cost of the drugs and
procedures is one of the major restraint for papillary thyroid cancer treatment market.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1659
Depending on geographic region, papillary thyroid cancer market is segmented into
seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East &
Africa. North America is estimated to contribute maximum revenue share in the global
market of Papillary Thyroid Cancer followed by Europe. Asia Pacific regions is expected to
grow at a higher growth rate owing to high occurrence of cancer diseases. Middle East &
Africa is expected to show a healthy growth rate in the forecast period
Report
Description
Report Description
Key players of papillary thyroid cancer market are Mylan pharmaceuticals Inc., Baxter
International Inc., Alara Pharmaceutical Corporation, Abbott laboratories, Bristol Myers
co., Teva parenteral medicines Inc., Jerome Stevens Pharmaceuticals Inc., and App
pharmaceuticals llc.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705